Table 1.
Baseline characteristics of COVID-19 cases aged 50 and older (Jan 1 to May 15, 2022)
| Characteristic | Prescribed nirmatrelvir plus ritonavir | Not prescribed nirmatrelvir plus ritonavir | p |
|---|---|---|---|
| No. | 6036 | 24286 | |
| Age (%) | <0.001 | ||
| 50 to 64 | 2745 (45.5) | 15084 (62.1) | |
| 65 to 79 | 2693 (44.6) | 7391 (30.4) | |
| 80 and older | 598 (9.9) | 1811 (7.5) | |
| Male sex (%) | 2505 (41.5) | 9851 (40.6) | 0.189 |
| Race and ethnicity (%) | <0.001 | ||
| Asian | 171 (2.8) | 665 (2.7) | |
| Black | 103 (1.7) | 1124 (4.6) | |
| Hispanic or Latinx | 177 (2.9) | 1738 (7.2) | |
| Other or unavailable | 206 (3.4) | 1416 (5.8) | |
| White | 5379 (89.1) | 19343 (79.6) | |
| High zip code SES vulnerability (%) | 422 (7.0) | 3020 (12.4) | <0.001 |
| Vaccination status (%) | <0.001 | ||
| Vaccinated and boosted | 4623 (76.6) | 11776 (48.5) | |
| Vaccinated | 1048 (17.4) | 9002 (37.1) | |
| Partially vaccinated | 96 (1.6) | 703 (2.9) | |
| Unvaccinated | 269 (4.5) | 2805 (11.5) | |
| Last vaccine dose more than 20 weeks prior (%) | 4821 (79.9) | 14990 (61.7) | <0.001 |
| Comorbidity score (%) | <0.001 | ||
| MASS 3 or less | 2821 (46.7) | 14940 (61.5) | |
| MASS 4 and 5 | 1089 (18.0) | 3611 (14.9) | |
| MASS 6 or greater | 2126 (35.2) | 5735 (23.6) | |
| Body mass index (BMI) (%) | <0.001 | ||
| BMI less than 25 or unavailable | 1851 (30.7) | 8880 (36.6) | |
| BMI 25 to 30 | 2154 (35.7) | 7643 (31.5) | |
| BMI 30 to 35 | 1250 (20.7) | 4753 (19.6) | |
| BMI greater than 35 | 781 (12.9) | 3010 (12.4) | |
| Immunocompromise (%) | 2836 (47.0) | 8749 (36.0) | <0.001 |
| Diabetes (%) | 1254 (20.8) | 4218 (17.4) | <0.001 |
| Heart disease or stroke (%) | 1020 (16.9) | 3054 (12.6) | <0.001 |
| Pulmonary disease (%) | 564 (9.3) | 1719 (7.1) | <0.001 |
| Bipolar, schizophrenia, and other disorders (%) | 128 (2.1) | 727 (3.0) | <0.001 |
| Depression and anxiety (%) | 1466 (24.3) | 4667 (19.2) | <0.001 |
| Hematologic malignancy (%) | 289 (4.8) | 694 (2.9) | <0.001 |
| Solid tumor malignancy (%) | 2224 (36.8) | 6538 (26.9) | <0.001 |
| Rheumatologic or inflammatory bowel disease (%) | 851 (14.1) | 2318 (9.5) | <0.001 |
Numbers are No. (%) unless otherwise noted. Immunocompromise includes patients with active malignancy and patients on immunosuppressive medications